← Back to Search

Virus Therapy

PSMA-Targeted Trillium Compounds + PTI-122 for Prostate Cancer

Phase < 1
Waitlist Available
Research Sponsored by Ratio Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up over 168 hours post-injection
Awards & highlights
No Placebo-Only Group

Summary

This trial tests special compounds that target prostate cancer cells in men with advanced disease. These compounds are labeled with a radioactive substance to track them in the body and are tested with and without a protective agent to see if it reduces side effects.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~over 168 hours post-injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and over 168 hours post-injection for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Amount of radioactivity in blood
Amount of radiotracer absorbed by organs
Amount of radiotracer absorbed by tumor
Secondary study objectives
Amount of PTI-122 in blood
Incidence of adverse events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Trillium Compound AloneExperimental Treatment1 Intervention
Single dose of PSMA-Targeted \[In-111\]-Labeled Trillium Compound
Group II: Trillium Compound + Single Dose PTI-122Experimental Treatment2 Interventions
Single dose of PSMA-Targeted \[In-111\]-Labeled Trillium Compound plus single dose of PTI-122 at 5, 10 or 15 mg
Group III: Trillium Compound + Multiple Dose PTI-122Experimental Treatment2 Interventions
Single dose of PSMA-Targeted \[In-111\]-Labeled Trillium Compound plus two doses of PTI-122 at the preferred dose level
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PSMA-Targeted [In-111]-Labeled Trillium Compound
2022
Completed Early Phase 1
~30
PTI-122
2022
Completed Early Phase 1
~30

Find a Location

Who is running the clinical trial?

Ratio Therapeutics, Inc.Lead Sponsor
John Babich, PhDStudy DirectorRatio Therapeutics, Inc.

Media Library

PSMA-Targeted [In-111]-Labeled Trillium Compound (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05773703 — Phase < 1
Prostate Cancer Research Study Groups: Trillium Compound Alone, Trillium Compound + Single Dose PTI-122, Trillium Compound + Multiple Dose PTI-122
Prostate Cancer Clinical Trial 2023: PSMA-Targeted [In-111]-Labeled Trillium Compound Highlights & Side Effects. Trial Name: NCT05773703 — Phase < 1
PSMA-Targeted [In-111]-Labeled Trillium Compound (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05773703 — Phase < 1
~8 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top